AZN · story · 26 October
AstraZeneca · 4 headlines from 4 outlets, on 26 October 2026.
Outlets report AstraZeneca's cancer data showcase at ESMO.
The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone.
WSJ is the largest at 7.5, ahead of STAT (7.5). Demokratis.co.id is the smallest at 5.8.
Source: MarketFrame news analysis
| outlet | Average tone |
|---|---|
| WSJ | 7.5 |
| STAT | 7.5 |
| Breakingthenews.net | 6.7 |
| Demokratis.co.id | 5.8 |
| Outlet | Headlines | Average tone |
|---|---|---|
| WSJ | 1 | +7.5 |
| STAT | 1 | +7.5 |
| Breakingthenews.net | 1 | +6.7 |
| Demokratis.co.id | 1 | +5.8 |
One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.
| Tone | What the article reported, and why it scored that way |
|---|---|
| +7.5 | New targeted therapy portfolio being readied |
| +7.5 | ESMO showcase of cancer pipeline |
| +6.7 | Cancer drug advancing |
| +5.8 | Data showcase at ESMO, mostly factual |
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.